Ardelyx, Inc.ARDX
What Ardelyx, Inc. does.
We are a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. We currently market two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor that was discovered and developed by Ardelyx. NHE3 is an antiporter expressed on the apical surface of the small and large intestines. Tenapanor is a minimally absorbed, first-in-class, oral, small molecule therapy.
Tenapanor, branded as IBSRELA ® , is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation. We believe that IBSRELA can bring meaningful benefit to the approximately 13 million Americans who suffer from the symptoms of IBS-C, many of whom continue to experience symptoms despite intervention with other therapies. We are seeking to further expand the IBSRELA eligible patient population to include patients with chronic idiopathic constipation (CIC), and have initiated a Phase 3 clinical trial evaluating tenapanor in adult CIC patients.
Tenapanor, branded as XPHOZAH ® , is approved in the U.S. to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. We believe XPHOZAH can bring meaningful relief to adult chronic kidney disease patients on dialysis, the vast majority of whom have elevated levels of serum phosphorus and are unable to achieve target serum phosphorus levels with phosphate binders alone. Continually elevated levels of serum phosphorus can result in severe cardiovascular health complications.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $7.6M | $10.1M | $52.2M | $124.5M | $333.6M | $407.3M |
| Net income | -$94.3M | -$158.2M | -$67.2M | -$66.1M | -$39.1M | -$61.6M |
| Free cash flow | -$81.8M | -$154.4M | -$70.1M | -$90.1M | -$45.8M | -$44.0M |
More on ARDX.
- Ardelyx, Inc. summary
- Ardelyx, Inc. financial statements
- Ardelyx, Inc. key metrics
- Ardelyx, Inc. health scores and style box
- Ardelyx, Inc. earnings
- Ardelyx, Inc. dividends
- Ardelyx, Inc. valuation
- Ardelyx, Inc. ownership and insiders
- Ardelyx, Inc. peers
Figures from Ardelyx, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.